Metoprolol xl
Pro Research Analysisby 
Searched over 200M research papers for "metoprolol xl"
Metoprolol CR/XL: Efficacy and Safety in Chronic Heart Failure and Other Conditions
Introduction to Metoprolol CR/XL
Metoprolol CR/XL (controlled release/extended release) is a beta1-selective beta-blocker widely used in the management of various cardiovascular conditions, including chronic heart failure, hypertension, and atrial fibrillation. This article synthesizes findings from multiple studies to highlight the efficacy, safety, and tolerability of metoprolol CR/XL in these conditions.
Metoprolol CR/XL in Chronic Heart Failure
Mortality and Hospitalization Reduction
The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) demonstrated significant benefits of metoprolol CR/XL in patients with chronic heart failure. The study included 3,991 patients with New York Heart Association (NYHA) class II-IV heart failure and an ejection fraction of 0.40 or less. Results showed a 34% reduction in all-cause mortality and significant decreases in sudden deaths and deaths from worsening heart failure Hjalmarson1999Prakash2000. Additionally, metoprolol CR/XL reduced hospitalizations for heart failure by 37% in diabetic patients and 35% in non-diabetic patients .
Dose-Response and Individualized Treatment
A post-hoc analysis of MERIT-HF indicated that both high-dose (over 100 mg) and low-dose (100 mg or less) metoprolol CR/XL provided similar mortality benefits, suggesting that individualized dose titration based on patient tolerability and heart rate response is effective . This supports the use of metoprolol CR/XL across a range of dosages tailored to individual patient needs.
Benefits in Severe Heart Failure
Patients with severe heart failure (NYHA class III/IV and ejection fraction <0.25) also benefited from metoprolol CR/XL, with significant reductions in total mortality, sudden death, and hospitalizations for worsening heart failure . These findings underscore the drug's efficacy even in more advanced stages of heart failure.
Metoprolol CR/XL in Special Populations
Patients with Diabetes
Patients with diabetes and chronic heart failure face a higher risk of hospitalization. Metoprolol CR/XL was well tolerated in this group and significantly reduced the risk of hospitalization for heart failure, demonstrating similar survival benefits in both diabetic and non-diabetic patients .
Female Patients
Women with heart failure, including those with severe conditions, experienced significant reductions in all-cause mortality, cardiovascular hospitalizations, and hospitalizations for worsening heart failure when treated with metoprolol CR/XL. These benefits were consistent with those observed in male patients, highlighting the drug's efficacy across genders .
Patients with Hypertension
In patients with a history of hypertension complicated by chronic systolic heart failure, metoprolol CR/XL significantly reduced total mortality, sudden death, and hospitalizations for worsening heart failure. This subgroup analysis from MERIT-HF confirms that hypertensive patients derive similar benefits from metoprolol CR/XL as the broader heart failure population .
Metoprolol CR/XL in Atrial Fibrillation
A study assessing the efficacy of metoprolol CR/XL in maintaining sinus rhythm after cardioversion of persistent atrial fibrillation found that the drug significantly reduced the risk of relapse into atrial fibrillation compared to placebo. Additionally, patients who relapsed into atrial fibrillation had a lower heart rate when treated with metoprolol CR/XL, indicating effective heart rate control .
Metoprolol CR/XL and Carotid Atherosclerosis
The β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) demonstrated that low-dose metoprolol CR/XL (25 mg once daily) reduced the progression of carotid intima-media thickness (IMT), suggesting a potential role in slowing atherosclerosis development. This effect was observed in clinically healthy subjects with carotid plaque, indicating broader cardiovascular protective benefits .
Conclusion
Metoprolol CR/XL is a well-tolerated and effective treatment for chronic heart failure, providing significant reductions in mortality and hospitalizations across various patient subgroups, including those with diabetes, severe heart failure, and hypertension. Additionally, it shows promise in maintaining sinus rhythm in atrial fibrillation and slowing the progression of carotid atherosclerosis. These findings support the broad utility of metoprolol CR/XL in managing cardiovascular conditions.
Sources and full results
Most relevant research papers on this topic